Jpmorgan Chase & CO Omega Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Omega Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 504 shares of OMGA stock, worth $524. This represents 0.0% of its overall portfolio holdings.

Number of Shares

504

Previous 10,098 95.01%

Holding current value

$524

Previous $36,000 97.22%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$1.86 - $3.2 $17,844 - $30,700	-9,594 Reduced 95.01%	504 $1,000
Q1 2024 May 10, 2024	SELL	$2.73 - $5.32 $15,558 - $30,318	-5,699 Reduced 36.08%	10,098 $36,000
Q4 2023 Feb 12, 2024	SELL	$1.35 - $3.21 $13,911 - $33,079	-10,305 Reduced 39.48%	15,797 $47,000
Q3 2023 Nov 14, 2023	BUY	$2.15 - $5.68 $10,274 - $27,144	4,779 Added 22.41%	26,102 $56,000
Q2 2023 Aug 11, 2023	BUY	$5.6 - $9.66 $109,978 - $189,712	19,639 Added 1166.21%	21,323 $119,000
Q1 2023 May 11, 2023	BUY	$4.81 - $10.95 $615 - $1,401	128 Added 8.23%	1,684 $10,000
Q4 2022 Feb 13, 2023	SELL	$4.22 - $7.05 $5,165 - $8,629	-1,224 Reduced 44.03%	1,556 $9,000
Q3 2022 Nov 14, 2022	BUY	$3.63 - $6.65 $3,183 - $5,832	877 Added 46.09%	2,780 $15,000
Q2 2022 Aug 11, 2022	SELL	$2.01 - $7.19 $32,817 - $117,391	-16,327 Reduced 89.56%	1,903 $7,000
Q1 2022 May 11, 2022	BUY	$6.24 - $14.04 $57,676 - $129,771	9,243 Added 102.85%	18,230 $113,000
Q4 2021 Feb 10, 2022	BUY	$11.33 - $29.38 $69,736 - $180,833	6,155 Added 217.34%	8,987 $102,000
Q3 2021 Nov 12, 2021	BUY	$16.0 - $22.51 $45,312 - $63,748	2,832 New	2,832 $53,000

Others Institutions Holding OMGA

# of Institutions

Shares Held

45.4M

Call Options Held

36.9K

Put Options Held

33.5K

View Full List

About Omega Therapeutics, Inc.

Ticker OMGA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,853,400
Market Cap $49.8M
Description
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-...

More about OMGA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Omega Therapeutics, Inc. Transaction History